Clinical trials: Anti-Retroviral Agents
HIV Infections
A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients
To compare the long-term virologic response to combination therapy with two protease inhibitors, i.e., nelfinavir (NFV) + saquinavir soft gel capsule (SQVsgc) and delavirdine (DLV) or combination lamivudine/zidovudine (3TC/ZDV…
- Trial name
- NCT00001094
- Testing
- Lamivudine/Zidovudine, Nelfinavir mesylate, Saquinavir
- Where
- 17 sites in United States, Puerto Rico
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Patients
Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP )
This is a prospective multicenter cohort study. The question arises as to whether treatment with protease inhibitors (PIs) could have a preventive role for COVID-19 infection, especially since patients living with HIV (PLWHIV)…
- Trial name
- NCT04357639
- Testing
- No intervention
- Where
- 6 sites in France
- Volunteers
- 1,040 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
HIV-1 Infection
Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study)
The AELIX-002 trial has been conducted on a cohort of individuals who started cART within the first 6 months after the primary VIH infection, thus increasing the likelihood of observing a certain rate of post-treatment controls…
- Trial name
- NCT04385875
- Testing
- Vaccine + extension of the ATI period
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
HIV Seropositivity
Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine
HIV+ patients are considered at risk for excessive bone fragility. Several factors could contribute: age, male sex, low body mass index (BMI), HIV infection per se, vitamin D deficiency, using tenofovir/a protease inhibitor (time…
- Trial name
- NCT01813292
- Where
- France
- Volunteers
- 103 people
- Sponsor
- Hopital Lariboisière
Lactating Women on Select DOI, Breastmilk Fed Infants of Mothers on Select DOI
Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana
The purpose of this study is to characterize the pharmacokinetics (PK) of understudied drugs administered to lactating women, receiving antiretroviral drugs per SOC as prescribed by their healthcare provider, and their…
- Conditions
- Lactating Women on Select DOI, Breastmilk Fed Infants of Mothers on Select DOI, HIV Infections
- Trial name
- BMS02 (NCT04862975)
- Testing
- Dolutegravir, Lamivudine, Emtricitabine
- Where
- 4 sites in South Africa
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Duke University
HIV Infection
Single DermaVir Immunization in HIV-1 Infected Patients on HAART
DermaVir is a plasmid DNA-containing synthetic nanomedicine. It is administered topically with DermaPrep to target Langerhans cells.
- Trial name
- GIHU004 (NCT00712530)
- Testing
- DermaVir, HAART
- Where
- Hungary
- Volunteers
- 9 people
- Sponsor
- Genetic Immunity
Human Immunodeficiency Virus (HIV)
ComBaCaL HIV Prevention TwiCs
This cluster-randomized intervention is embedded in the ComBaCaL (Community-Based Chronic disease care Lesotho) cohort study (EKNZ ID AO_2022-00058, clinicaltrials.gov ID NCT05596773, Lesotho NH-REC ID 210-2022), a platform for…
- Trial name
- CoPrev (NCT07581600)
- Testing
- CoPrev model, Referral to the nearest responsible health facility
- Where
- 2 sites in Lesotho, Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
HIV
Post Analytic Treatment Interruption Study
This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI).
- Trial name
- NCT02761200
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- SEARCH Research Foundation
Infection, Human Immunodeficiency Virus I, HIV Infection
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily.
- Trial name
- NCT00082394
- Testing
- Trizivir, atazanavir, Combivir
- Where
- 45 sites in United States, Mexico
- Sponsor
- GlaxoSmithKline
HIV-1 Infection
Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
The objective of this study is to evaluate the safety and efficacy of a regimen containing cobicistat-boosted atazanavir (ATV+COBI) plus emtricitabine/tenofovir disoproxil fumarate (Truvada®; FTC/TDF) versus ritonavir-boosted…
- Trial name
- NCT00892437
- Testing
- COBI, RTV, ATV
- Where
- 31 sites in United States
- Volunteers
- 85 people
- Sponsor
- Gilead Sciences
HIV Infections
HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)
This study will investigate low-level viral loads in HIV-infected patients taking highly active antiretroviral therapy (HAART). Although HAART reduces viral levels and restores immune function to some degree, it does not cure HIV…
- Trial name
- NCT00043641
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Cardiovascular Diseases
Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications
People infected with HIV have a greater risk of developing cardiovascular disease than people not infected with HIV. This may be due to increased inflammation brought on by either the HIV infection itself or the use of…
- Conditions
- HIV, Cardiovascular Diseases, Atherosclerosis
- Trial name
- NCT00796822
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Indiana University
HIV
Strategies to Optimize Antiretroviral Therapy Services for Maternal & Child Health: the MCH-ART Study
The purpose of this study is to understand how to improve health care services for HIV-positive women during their pregnancy and after delivery.
- Trial name
- MCH-ART (NCT01933477)
- Testing
- MCH-focused ART services
- Where
- South Africa
- Volunteers
- 1,554 people
- Sponsor
- University of Cape Town
HIV
TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.
The purpose of this study is to compare the efficacy, safety and tolerability of TMC114/r versus Kaletra (a combination pill of lopinavir and ritonavir, ("lpv/rtv") in HIV-1 infected patients who have never been treated with…
- Trial name
- NCT00258557
- Testing
- LPV/RTV, TMC-114/RTV
- Where
- 89 sites in United States, Argentina and 23 more
- Volunteers
- 692 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Lymphoma, AIDS Related, HIV Infections
A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL
No standard regimen currently exists for the treatment of AIDS-related lymphoma. Based on the encouraging NCI results with DA-EPOCH, the US AIDS Malignancy Consortium is currently administering a phase II randomized protocol…
- Trial name
- CATCH (NCT00799136)
- Testing
- R-EPOCH and cART
- Where
- 2 sites in Canada
- Volunteers
- 6 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Body Weight Changes, Human Immunodeficiency Virus
Doravirine and Weight Gain in Antiretroviral Naive
The purpose of this study is determine whether different antiretroviral therapy (ART) changes the effects on body fat and predict the weight change in Black and Hispanic females.
- Conditions
- Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity
- Trial name
- DAWN (NCT05457530)
- Testing
- DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Prism Health North Texas
HIV/AIDS
Project YES! Youth Engaging for Success
Youth-led strategies remain untested in clinic-based programs to achieve viral suppression (VS) and reduce self-stigma (feelings of worthlessness/shame) among adolescents and young adults (AYA) living with HIV in sub-Saharan…
- Trial name
- Project YES! (NCT04115813)
- Testing
- Project YES! Youth Engaging for Success
- Where
- Zambia
- Volunteers
- 276 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV/AIDS, ANTIRETROVIRAL TREATMENT
Immediate ART in Subjects With Opportunistic Diseases
The aim of this study is to compare the clinical response and mortality rate due to opportunistic disease in HIV-infected individuals who start immediate versus conventional antiretroviral therapy (ART).
- Trial name
- TARi (NCT03825523)
- Testing
- Antiretroviral Therapy (ART)
- Where
- Mexico
- Volunteers
- 114 people
- Sponsor
- Gustavo Reyes-Teran
HIV Infections
Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
This study is to test a therapeutic HIV-1 vaccine (HIVAX™) in HIV-1 infected subjects. The safety and immune responses will be studied in vaccine recipients.
- Trial name
- GCHT01 (NCT01428596)
- Testing
- HIVAX, saline solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GeneCure Biotechnologies
HIV Seropositivity, Adherence, Medication
Supporting Health Behavior Among Persons Living With HIV Using Tech, MOST, and Behavioral Economics
The present study focuses on adult persons living with HIV in the New York City and Newark, New Jersey metropolitan areas who are not highly adherent to HIV medication and who do not evidence undetectable HIV viral load (the…
- Trial name
- SCAP2 (NCT04518241)
- Testing
- MI sessions, TMQQ, Type of compensation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- New York University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.